“Dr. Anan” tells good news about the new dengue fever vaccine. It will soon be available again after the Phase 3 test results found that it can prevent disease at nearly 80%.
Dr. Anan Jongkaewwattana, Director of the Animal Health Innovation and Management Research Group The National Center for Genetic Engineering and Biotechnology (Biotech) posted on its Facebook page. Anan Jongkaewwattana Regarding the new dengue fever vaccine, stating that
A new dengue vaccine is about to be released soon after results from Phase 3 testing on more than 16,000 volunteers, collected over three years of data in Brazil, showing nearly 80% efficacy in preventing the disease.
This new vaccine is called Butantan–Dengue Vaccine (Butantan-DV) after a research institute in Brazil. Research recently published in the journal NJEM indicates that the vaccine is 96.8% effective at protecting against DENV 1 in previously infected populations.
But if you’ve never had a landscape before Immunity from the vaccine provides 85.5% protection, while DENV2 is reduced. People who have been previously infected when vaccinated have 83.6% protection, and people who have never been infected have 57.9% protection.
Data on DENV3 and DENV4 are not available because these two serotypes are only rarely found in Brazil. resulting in insufficient data collection
This vaccine received technology transferred from the NIH of the United States, formerly known as TV003, which is a combination of four strains of dengue fever virus that have been modified to make them attenuated. It was created in a laboratory with some parts missing. Then created as a recombinant virus (rDENV) until it does not cause disease. But still has the ability to stimulate the immune system.
Read more: How Junk Food Affects Your Deep Sleep: Findings from a New Study
This vaccine is similar to 4 strains of real natural viruses that were developed separately. It is different from the first two forms of dengue vaccine, Denvaxia, which was developed from The core of the yellow fever virus was then replaced with genes that stimulate the immune system of each DENV strain in place of the original yellow fever virus genes. This makes the vaccine a hybrid virus of yellow fever and dengue fever.
As for Tak-003 or QDENGA that is available in Thailand It will be a virus that uses DENV2 as the core and then replaces the genes of DENV1, DENV3, and DENV4 with the original DENV2 genes to create a DENV2-and other DENV hybrid virus instead.
The advantage of Butantan-DV is that the vaccine is administered in just one dose. without limiting whether the person has been infected before or not And because it uses real viruses from all 4 strains, the body can see the whole virus. This includes other proteins of the virus that other forms of vaccine do not have. This may help the body create T cells to better protect against viruses. It is considered a vaccine that is worth following and may actually be used soon.